|
1
|
Hanvic B and Ray-Coquard I: Gynecological
sarcomas: Literature review of 2020. Curr Opin Oncol. 33:345–350.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Korenaga TK and Tewari KS: Gynecologic
cancer in pregnancy. Gynecol Oncol. 157:799–809. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marcolin JC, Lichtenfels M, da Silva CA
and de Farias CB: Gynecologic and breast cancers: What's new in
chemoresistance and chemosensitivity tests? Curr Probl Cancer.
47:1009962023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alizadeh H, Akbarabadi P, Dadfar A, Tareh
MR and Soltani B: A comprehensive overview of ovarian cancer stem
cells: Correlation with high recurrence rate, underlying
mechanisms, and therapeutic opportunities. Mol Cancer. 24:1352025.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh
M, Nabavi N, Sethi G, Zhao P and Liu S: Advances in cancer
immunotherapy: Historical perspectives, current developments, and
future directions. Mol Cancer. 24:1362025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenbaum SR, Hughes CJ, Fields KM, Purdy
SC, Gustafson AL, Wolin A, Hampton D, Shrivastava NM, Turner N,
Danis E, et al: EYA3 regulation of NF-κB and CCL2 suppresses
cytotoxic NK cells in the premetastatic niche to promote TNBC
metastasis. Sci Adv. 11:eadt05042025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Konstantinopoulos PA and Matulonis UA:
Clinical and translational advances in ovarian cancer therapy. Nat
Cancer. 4:1239–1257. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gupta R, Kumar R, Penn CA and Wajapeyee N:
Immune evasion in ovarian cancer: Implications for immunotherapy
and emerging treatments. Trends Immunol. 46:166–181. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Makker V, MacKay H, Ray-Coquard I, Levine
DA, Westin SN, Aoki D and Oaknin A: Endometrial cancer. Nat Rev Dis
Primers. 7:882021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burd EM: Human papillomavirus and cervical
cancer. Clin Microbiol Rev. 16:1–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qin SY, Cheng YJ, Lei Q, Zhang AQ and
Zhang XZ: Combinational strategy for high-performance cancer
chemotherapy. Biomaterials. 171:178–197. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zemek RM, Anagnostou V, Pires da Silva I,
Long GV and Lesterhuis WJ: Exploiting temporal aspects of cancer
immunotherapy. Nat Rev Cancer. 24:480–497. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stewart MD, Keane A, Butterfield LH,
Levine BL, Thompson B, Xu Y, Ramsborg C, Lee A, Kalos M, Koerner C,
et al: Accelerating the development of innovative cellular therapy
products for the treatment of cancer. Cytotherapy. 22:239–246.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang X, Wei X, Shi L, Jiang H, Ma F, Li
Y, Li C and Ma Y and Ma Y: The latest research progress: Active
components of traditional Chinese medicine as promising candidates
for ovarian cancer therapy. J Ethnopharmacol. 337:1188112025.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shafabakhsh R and Asemi Z: Quercetin: A
natural compound for ovarian cancer treatment. J Ovarian Res.
12:552019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Z, Zhu W, Kong X, Chen X, Sun X, Zhang
W and Zhang R: Tanshinone IIA inhibits glucose metabolism leading
to apoptosis in cervical cancer. Oncol Rep. 42:1893–1903.
2019.PubMed/NCBI
|
|
17
|
Zhang X, Zhu L, Wang X, Zhang H, Wang L
and Xia L: Basic research on curcumin in cervical cancer: Progress
and perspectives. Biomed Pharmacother. 162:1145902023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sandhu SS, Rouz SK, Kumar S, Swamy N,
Deshmukh L, Hussain A, Haque S and Tuli HS: Ursolic acid: A
pentacyclic triterpenoid that exhibits anticancer therapeutic
potential by modulating multiple oncogenic targets. Biotechnol
Genet Eng Rev. 39:729–759. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kashyap D, Tuli HS and Sharma AK: Ursolic
acid (UA): A metabolite with promising therapeutic potential. Life
Sci. 146:201–213. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun Q, He M, Zhang M, Zeng S, Chen L, Zhou
L and Xu H: Ursolic acid: A systematic review of its pharmacology,
toxicity and rethink on its pharmacokinetics based on PK-PD model.
Fitoterapia. 147:1047352020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cargnin ST and Gnoatto SB: Ursolic acid
from apple pomace and traditional plants: A valuable triterpenoid
with functional properties. Food Chem. 220:477–489. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramos-Hryb AB, Pazini FL, Kaster MP and
Rodrigues ALS: Therapeutic potential of ursolic acid to manage
neurodegenerative and psychiatric diseases. CNS Drugs.
31:1029–1041. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song YH, Jeong SJ, Kwon HY, Kim B, Kim SH
and Yoo DY: Ursolic acid from Oldenlandia diffusa induces apoptosis
via activation of caspases and phosphorylation of glycogen synthase
kinase 3 beta in SK-OV-3 ovarian cancer cells. Biol Pharm Bull.
35:1022–1028. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Li T, Gong ES and Liu RH:
Antiproliferative activity of ursolic acid in MDA-MB-231 human
breast cancer cells through Nrf2 pathway regulation. J Agric Food
Chem. 68:7404–7415. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yim EK, Lee KH, Namkoong SE, Um SJ and
Park JS: Proteomic analysis of ursolic acid-induced apoptosis in
cervical carcinoma cells. Cancer Lett. 235:209–220. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khwaza V and Aderibigbe BA: Potential
pharmacological properties of triterpene derivatives of ursolic
acid. Molecules. 29:38842024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi Y, Leng Y, Liu D, Liu X, Ren Y, Zhang
J and Chen F: Research advances in protective effects of ursolic
acid and oleanolic acid against gastrointestinal diseases. Am J
Chin Med. 49:413–435. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu HR, Ahmad N, Lv B and Li C: Advances
in production and structural derivatization of the promising
molecule ursolic acid. Biotechnol J. 16:e20006572021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giacinti G, Raynaud C, Capblancq S and
Simon V: Evaluation and prevention of the negative matrix effect of
terpenoids on pesticides in apples quantification by gas
chromatography-tandem mass spectrometry. J Chromatogr A. 1483:8–19.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li H, Liu Y, Guo S, Shi M, Qin S and Zeng
C: Extraction of ursolic acid from apple peel with hydrophobic deep
eutectic solvents: comparison between response surface methodology
and artificial neural networks. Foods. 12:3102023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xia EQ, Yu YY, Xu XR, Deng GF, Guo YJ and
Li HB: Ultrasound-assisted extraction of oleanolic acid and ursolic
acid from Ligustrum lucidum Ait. Ultrason Sonochem. 19:772–776.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xia EQ, Wang BW, Xu XR, Zhu L, Song Y and
Li HB: Microwave-assisted extraction of oleanolic acid and ursolic
acid from Ligustrum lucidum Ait. Int J Mol Sci. 12:5319–5329. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
K V, L S, N V K, R P, M P DR, Suneetha C,
Palpandi Raja R and Muthusamy S: Promising approaches in the
extraction, characterization, and biotechnological applications of
ursolic acid: A review. Prep Biochem Biotechnol. 55:973–984. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mlala S, Oyedeji AO, Gondwe M and Oyedeji
OO: Ursolic acid and its derivatives as bioactive agents.
Molecules. 24:27512019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Khwaza V, Oyedeji OO and Aderibigbe BA:
Ursolic acid-based derivatives as potential anti-cancer agents: An
update. Int J Mol Sci. 21:59202020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Erdmann J, Kujaciński M and Wiciński M:
Beneficial effects of ursolic acid and its derivatives-focus on
potential biochemical mechanisms in cardiovascular conditions.
Nutrient. 13:39002021. View Article : Google Scholar
|
|
37
|
Lin W and Ye H: Anticancer activity of
ursolic acid on human ovarian cancer cells via ROS and MMP mediated
apoptosis, cell cycle arrest and downregulation of PI3K/AKT
pathway. J BUON. 25:750–756. 2020.PubMed/NCBI
|
|
38
|
Ganapathy-Kanniappan S and Geschwind JF:
Tumor glycolysis as a target for cancer therapy: Progress and
prospects. Mol Cancer. 12:1522013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu M, Li X, Yuan C, Zhu T, Wang M, Zhu Y,
Duan Y, Yao J, Luo B, Wang Z, et al: Ursolic acid inhibits
glycolysis of ovarian cancer via KLF5/PI3K/AKT signaling pathway.
Am J Chin Med. 52:2211–2231. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu H, Zou J, Li X, Ge Y and He W: Drug
delivery for platinum therapeutics. J Control Release. 380:503–523.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Talach T, Rottenberg J, Gal B, Kostrica R,
Jurajda M, Kocak I, Lakomy R and Vogazianos E: Genetic risk factors
of cisplatin induced ototoxicity in adult patients. Neoplasma.
63:263–268. 2016.PubMed/NCBI
|
|
42
|
Di Y, Xu T, Tian Y, Ma T, Qu D, Wang Y,
Lin Y, Bao D, Yu L, Liu S and Wang A: Ursolic acid protects against
cisplatin-induced ototoxicity by inhibiting oxidative stress and
TRPV1-mediated Ca2+-signaling. Int J Mol Med. 46:806–816. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li W, Luo L, Shi W, Yin Y and Gao S:
Ursolic acid reduces Adriamycin resistance of human ovarian cancer
cells through promoting the HuR translocation from cytoplasm to
nucleus. Environ Toxicol. 36:267–275. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Batlle E and Clevers H: Cancer stem cells
revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saw PE, Liu Q, Wong PP and Song E: Cancer
stem cell mimicry for immune evasion and therapeutic resistance.
Cell Stem Cell. 31:1101–1112. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang WJ, Sui H, Qi C, Li Q, Zhang J, Wu
SF, Mei MZ, Lu YY, Wan YT, Chang H and Guo PT: Ursolic acid
inhibits proliferation and reverses drug resistance of ovarian
cancer stem cells by downregulating ABCG2 through suppressing the
expression of hypoxia-inducible factor-1α in vitro. Oncol Rep.
36:428–440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang J, Wang W, Qian L, Zhang Q, Lai D
and Qi C: Ursolic acid inhibits the proliferation of human ovarian
cancer stem-like cells through epithelial-mesenchymal transition.
Oncol Rep. 34:2375–2384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yim EK, Lee MJ, Lee KH, Um SJ and Park JS:
Antiproliferative and antiviral mechanisms of ursolic acid and
dexamethasone in cervical carcinoma cell lines. Int J Gynecol
Cancer. 16:2023–2031. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Leng S, Hao Y, Du D, Xie S, Hong L, Gu H,
Zhu X, Zhang J, Fan D and Kung HF: Ursolic acid promotes cancer
cell death by inducing Atg5-dependent autophagy. Int J Cancer.
133:2781–2790. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guo JL, Han T, Bao L, Li XM, Ma JQ and
Tang LP: Ursolic acid promotes the apoptosis of cervical cancer
cells by regulating endoplasmic reticulum stress. J Obstet Gynaecol
Res. 45:877–881. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li Y, Xing D, Chen Q and Chen WR:
Enhancement of chemotherapeutic agent-induced apoptosis by
inhibition of NF-kappaB using ursolic acid. Int J Cancer.
127:462–473. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Achiwa Y, Hasegawa K and Udagawa Y: Effect
of ursolic acid on MAPK in cyclin D1 signaling and RING-type E3
ligase (SCF E3s) in two endometrial cancer cell lines. Nutr Cancer.
65:1026–1033. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Achiwa Y, Hasegawa K and Udagawa Y:
Molecular mechanism of ursolic acid induced apoptosis in poorly
differentiated endometrial cancer HEC108 cells. Oncol Rep.
14:507–512. 2005.PubMed/NCBI
|
|
54
|
Achiwa Y, Hasegawa K and Udagawa Y:
Regulation of the phosphatidylinositol 3-kinase-Akt and the
mitogen-activated protein kinase pathways by ursolic acid in human
endometrial cancer cells. Biosci Biotechnol Biochem. 71:31–37.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Achiwa Y, Hasegawa K, Komiya T and Udagawa
Y: Ursolic acid induces Bax-dependent apoptosis through the
caspase-3 pathway in endometrial cancer SNG-II cells. Oncol Rep.
13:51–57. 2005.PubMed/NCBI
|
|
56
|
De Angel RE, Smith SM, Glickman RD,
Perkins SN and Hursting SD: Antitumor effects of ursolic acid in a
mouse model of postmenopausal breast cancer. Nutr Cancer.
62:1074–1086. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang JS, Ren TN and Xi T: Ursolic acid
induces apoptosis by suppressing the expression of FoxM1 in MCF-7
human breast cancer cells. Med Oncol. 29:10–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kassi E, Sourlingas TG, Spiliotaki M,
Papoutsi Z, Pratsinis H, Aligiannis N and Moutsatsou P: Ursolic
acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast
cancer cells. Cancer Invest. 27:723–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mallepogu V, Sankaran KR, Pasala C, Bandi
LR, Maram R, Amineni UM and Meriga B: Ursolic acid regulates key
EMT transcription factors, induces cell cycle arrest and apoptosis
in MDA-MB-231 and MCF-7 breast cancer cells, an in-vitro and in
silico studies. J Cell Biochem. 124:1900–1918. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Manouchehri JM and Kalafatis M: Ursolic
acid promotes the sensitization of rhTRAIL-resistant
triple-negative breast cancer. Anticancer Res. 38:6789–6795. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Guo W, Xu B, Wang X, Zheng B, Du J and Liu
S: The analysis of the anti-tumor mechanism of ursolic acid using
connectively map approach in breast cancer cells line MCF-7. Cancer
Manag Res. 12:3469–3476. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kim GD: Ursolic acid decreases the
proliferation of MCF-7 cell-derived breast cancer stem-like cells
by modulating the ERK and PI3K/AKT signaling pathways. Prev Nutr
Food Sci. 26:434–444. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhao C, Yin S, Dong Y, Guo X, Fan L, Ye M
and Hu H: Autophagy-dependent EIF2AK3 activation compromises
ursolic acid-induced apoptosis through upregulation of MCL1 in
MCF-7 human breast cancer cells. Autophagy. 9:196–207. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gupta KB, Gao J, Li X, Thangaraju M, Panda
SS and Lokeshwar BL: Cytotoxic autophagy: A novel treatment
paradigm against breast cancer using oleanolic acid and ursolic
acid. Cancers (Basel). 16:33672024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lewinska A, Adamczyk-Grochala J,
Kwasniewicz E, Deregowska A and Wnuk M: Ursolic acid-mediated
changes in glycolytic pathway promote cytotoxic autophagy and
apoptosis in phenotypically different breast cancer cells.
Apoptosis. 22:800–815. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Fogde DL, Xavier CPR, Balnytė K, Holland
LKK, Stahl-Meyer K, Dinant C, Corcelle-Termeau E, Pereira-Wilson C,
Maeda K and Jäättelä M: Ursolic acid impairs cellular lipid
homeostasis and lysosomal membrane integrity in breast carcinoma
cells. Cells. 11:40782022. View Article : Google Scholar
|
|
67
|
Guerra ÂR, Paulino AF, Castro MM, Oliveira
H, Duarte MF and Duarte IF: Triple negative breast cancer and
breast epithelial cells differentially reprogram glucose and lipid
metabolism upon treatment with triterpenic acids. Biomolecules.
10:11632020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wang S, Chang X, Zhang J, Li J, Wang N,
Yang B, Pan B, Zheng Y, Wang X, Ou H and Wang Z: Ursolic acid
inhibits breast cancer metastasis by suppressing glycolytic
metabolism via activating SP1/caveolin-1 signaling. Front Oncol.
11:7455842021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mandal S, Gamit N, Varier L, Dharmarajan A
and Warrier S: Inhibition of breast cancer stem-like cells by a
triterpenoid, ursolic acid, via activation of Wnt antagonist, sFRP4
and suppression of miRNA-499a-5p. Life Sci. 265:1188542021.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liao WL, Liu YF, Ying TH, Shieh JC, Hung
YT, Lee HJ, Shen CY and Cheng CW: Inhibitory effects of ursolic
acid on the stemness and progression of human breast cancer cells
by modulating argonaute-2. Int J Mol Sci. 24:3662022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yang X, Liang B, Zhang L, Zhang M, Ma M,
Qing L, Yang H, Huang G and Zhao J: Ursolic acid inhibits the
proliferation of triple-negative breast cancer stem-like cells
through NRF2-mediated ferroptosis. Oncol Rep. 52:942024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yeh CT, Wu CH and Yen GC: Ursolic acid, a
naturally occurring triterpenoid, suppresses migration and invasion
of human breast cancer cells by modulating c-Jun N-terminal kinase,
Akt and mammalian target of rapamycin signaling. Mol Nutr Food Res.
54:1285–1295. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Luo J, Hu YL and Wang H: Ursolic acid
inhibits breast cancer growth by inhibiting proliferation, inducing
autophagy and apoptosis, and suppressing inflammatory responses via
the PI3K/AKT and NF-κB signaling pathways in vitro. Exp Ther Med.
14:3623–3631. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhang Y, Ma X, Li H, Zhuang J, Feng F, Liu
L, Liu C and Sun C: Identifying the effect of ursolic acid against
triple-negative breast cancer: Coupling network pharmacology with
experiments verification. Front Pharmacol. 12:6857732021.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lu Q, Chen W, Ji Y, Liu Y and Xue X:
Ursolic acid enhances cytotoxicity of doxorubicin-resistant
triple-negative breast cancer cells via ZEB1-AS1/miR-186-5p/ABCC1
axis. Cancer Biother Radiopharm. 37:673–683. 2022.PubMed/NCBI
|
|
76
|
Wang Z, Zhang P, Jiang H, Sun B, Luo H and
Jia A: Ursolic acid enhances the sensitivity of MCF-7 and
MDA-MB-231 cells to epirubicin by modulating the autophagy pathway.
Molecules. 27:33992022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zong L, Cheng G, Liu S, Pi Z, Liu Z and
Song F: Reversal of multidrug resistance in breast cancer cells by
a combination of ursolic acid with doxorubicin. J Pharm Biomed
Anal. 165:268–275. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zong L, Cheng G, Zhao J, Zhuang X, Zheng
Z, Liu Z and Song F: Inhibitory effect of ursolic acid on the
migration and invasion of doxorubicin-resistant breast cancer.
Molecules. 27:12822022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Luo F, Zhao J, Liu S, Xue Y, Tang D, Yang
J, Mei Y, Li G and Xie Y: Ursolic acid augments the
chemosensitivity of drug-resistant breast cancer cells to
doxorubicin by AMPK-mediated mitochondrial dysfunction. Biochem
Pharmacol. 205:1152782022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Xiang F, Fan Y, Ni Z, Liu Q, Zhu Z, Chen
Z, Hao W, Yue H, Wu R and Kang X: Ursolic acid reverses the
chemoresistance of breast cancer cells to paclitaxel by targeting
MiRNA-149-5p/MyD88. Front Oncol. 9:5012019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wang Y, Luo Z, Zhou D, Wang X, Chen J,
Gong S and Yu Z: Nano-assembly of ursolic acid with platinum
prodrug overcomes multiple deactivation pathways in
platinum-resistant ovarian cancer. Biomater Sci. 9:4110–4119. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Jin H, Pi J, Yang F, Jiang J, Wang X, Bai
H, Shao M, Huang L, Zhu H, Yang P, et al: Folate-chitosan
nanoparticles loaded with ursolic acid confer anti-breast cancer
activities in vitro and in vivo. Sci Rep. 6:307822016. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Fu H, Wu TH, Ma CP and Yen FL: Improving
water solubility and skin penetration of ursolic acid through a
nanofiber process to achieve better in vitro anti-breast cancer
activity. Pharmaceutics. 16:11472024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sharma R, Yadav V, Jha S, Dighe S and Jain
S: Unveiling the potential of ursolic acid modified hyaluronate
nanoparticles for combination drug therapy in triple negative
breast cancer. Carbohydr Polym. 338:1221962024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Liu CH, Wong SH, Tai CJ, Tai CJ, Pan YC,
Hsu HY, Richardson CD and Lin LT: Ursolic acid and its
nanoparticles are potentiators of oncolytic measles virotherapy
against breast cancer cells. Cancers (Basel). 13:1362021.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang S, Meng X and Dong Y: Ursolic acid
nanoparticles inhibit cervical cancer growth in vitro and in vivo
via apoptosis induction. Int J Oncol. 50:1330–1340. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Li W, Zhang H, Nie M, Tian Y, Chen X, Chen
C, Chen H and Liu R: Ursolic acid derivative FZU-03,010 inhibits
STAT3 and induces cell cycle arrest and apoptosis in renal and
breast cancer cells. Acta Biochim Biophys Sin (Shanghai).
49:367–373. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li W, Zhang H, Nie M, Wang W, Liu Z, Chen
C, Chen H, Liu R, Baloch Z and Ma K: A novel synthetic ursolic acid
derivative inhibits growth and induces apoptosis in breast cancer
cell lines. Oncol Lett. 15:2323–2329. 2018.PubMed/NCBI
|
|
89
|
Tang Q, Liu Y, Li T, Yang X, Zheng G, Chen
H, Jia L and Shao J: A novel co-drug of aspirin and ursolic acid
interrupts adhesion, invasion and migration of cancer cells to
vascular endothelium via regulating EMT and EGFR-mediated signaling
pathways: Multiple targets for cancer metastasis prevention and
treatment. Oncotarget. 7:73114–73129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Pattnaik B, Lakshmi JK, Kavitha R,
Jagadeesh B, Bhattacharjee D, Jain N and Mallavadhani UV:
Synthesis, structural studies, and cytotoxic evaluation of novel
ursolic acid hybrids with capabilities to arrest breast cancer
cells in mitosis. J Asian Nat Prod Res. 19:260–271. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Gou W, Luo N, Yu B, Wu H, Wu S, Tian C,
Guo J, Ning H, Bi C, Wei H, et al: Ursolic acid derivative UA232
promotes tumor cell apoptosis by inducing endoplasmic reticulum
stress and lysosomal dysfunction. Int J Biol Sci. 18:2639–2651.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wang M, Gu C, Yang Y, Chen L, Chen K, Du
J, Wu H and Li Y: Ursolic acid derivative UAOS-Na treats
experimental autoimmune encephalomyelitis by immunoregulation and
protecting myelin. Front Neurol. 14:12698622023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Xu FF, Shang Y, Wei HQ, Zhang WY, Wang LX,
Hu T, Zhang SQ, Li YL, Shang HH, Hou WB, et al: Ursolic acid
derivative UA312 ameliorates ionizing radiation-induced
cardiotoxicity and neurodevelopmental toxicity in zebrafish via
targeting chrna3 and grik5. Acta Pharmacol Sin. April 28–2025.(Epub
ahead of print). View Article : Google Scholar
|
|
94
|
da Silva EF, de Vargas AS, Willig JB, de
Oliveira CB, Zimmer AR, Pilger DA, Buffon A and Gnoatto SCB:
Synthesis and antileukemic activity of an ursolic acid derivative:
A potential co-drug in combination with imatinib. Chem Biol
Interact. 344:1095352021. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Shanmugam MK, Dai X, Kumar AP, Tan BK,
Sethi G and Bishayee A: Ursolic acid in cancer prevention and
treatment: molecular targets, pharmacokinetics and clinical
studies. Biochem Pharmacol. 85:1579–1587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Antonio E, Dos Reis Antunes Junior O,
Marcano RGDJV, Diedrich C, da Silva Santos J, Machado CS, Khalil NM
and Mainardes RM: Chitosan modified poly (lactic acid)
nanoparticles increased the ursolic acid oral bioavailability. Int
J Biol Macromol. 172:133–142. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Namdeo P, Gidwani B, Tiwari S, Jain V,
Joshi V, Shukla SS, Pandey RK and Vyas A: Therapeutic potential and
novel formulations of ursolic acid and its derivatives: An updated
review. J Sci Food Agric. 103:4275–4292. 2023. View Article : Google Scholar : PubMed/NCBI
|
